glp 1 drugs and cancer GLP-1 Receptor Agonists in Solid Tumour Therapy: Exploring Their Anticancer Potential Underlying Molecular Pathways GLP-1 Drugs May Protect Against
Description
doi: 10.1007/s00296-016-3481-8 95 BinduSMazumderSBandyopadhyayU
Clinical evidence (based on the literature) on GLP-1 RAs licensed in South Asia or under regulatory approval in one or more South Asian countries is presented and based on prescription pattern and the geography of the reported patient group
& Crofford, L
Diabetes Obes Metab (2020) 22:93846
Future Directions Tirzepatide represents just the beginning of multi-agonist approaches
This in turn reduces the amount of insulin the body needs, ultimately resulting in reduced hyperglycemia and improved control of glucose levels
